Vapor Ablation for Localized Cancer Lesions

Sponsor
Uptake Medical Technology, Inc.
Study ID
NCT03514329
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bronchoscopic Thermal Vapor Ablation — DEVICE
    Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.

Study Details

This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung. Patients who have consented to participate in this study (enrolled) will be subject to eligibility screening and baseline assessments, prior to undergoing the BTVA-C procedure. Only patients that meet all of the inclusion criteria and none of the exclusion criteria will receive vapor ablation treatment. Patients will be followed for up to 12 months.

Key Dates

First listed
May 2, 2018
Start date
Sep 1, 2026
Status verified
Feb 2025
Primary completion
Mar 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vapor Ablation
    Patients treated with Bronchoscopic Thermal Vapor Ablation for lung cancer

Primary Outcome Measure

BTVA-C related AEs/SAEs [ Time Frame: up to 6 months post-ablation ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies